{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:58Z","timestamp":1753891078268,"version":"3.41.2"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-INBS-0008","ANR-10-EQPX-02-01"],"award-info":[{"award-number":["ANR-11-INBS-0008","ANR-10-EQPX-02-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02096","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T05:59:46Z","timestamp":1599544786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals"],"prefix":"10.3389","volume":"11","author":[{"given":"Adrien","family":"Leite Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Jouhault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Marcos Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Le Grand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Tchitchek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030272","article-title":"Frequency of adverse events after vaccination with different vaccinia strains.","volume":"3","author":"Kretzschmar","year":"2006","journal-title":"PLoS Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1001\/jama.294.21.2734","article-title":"Adverse events associated with smallpox vaccination in the United States, January-October 2003.","volume":"294","author":"Casey","year":"2005","journal-title":"J Am Med Assoc."},{"key":"B3","first-page":"24","article-title":"[Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures].","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol Orig."},{"key":"B4","first-page":"253","article-title":"Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA.","volume":"107","author":"Mahnel","year":"1994","journal-title":"Berl Munch Tierarztl Wochenschr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox.","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/fon.12.7","article-title":"Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.","volume":"8","author":"Amato","year":"2012","journal-title":"Future Oncol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12998-6","article-title":"Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.","volume":"10","author":"Medina-Echeverz","year":"2019","journal-title":"Nat Commun."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus Ankara vaccines.","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial.","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains.","volume":"34","author":"Condit","year":"2017","journal-title":"Vaccine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.08.085","article-title":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.","volume":"37","author":"Kochhar","year":"2018","journal-title":"Vaccine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-017-0164-9","article-title":"Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design.","volume":"14","author":"Routy","year":"2017","journal-title":"AIDS Res Ther."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and Non-AIDS co-morbidities in HIV-infected patients under long-term ART.","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses."},{"key":"B14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/vaccines2010160","article-title":"DNA\/MVA vaccines for HIV\/AIDS.","volume":"2","author":"Iyer","year":"2014","journal-title":"Vaccines."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/gt.2010.90","article-title":"MVA- nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.","volume":"17","author":"Kutscher","year":"2010","journal-title":"Gene Ther."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141456","article-title":"A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART.","volume":"10","author":"G\u00f3mez","year":"2015","journal-title":"PLoS One."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1016\/j.vaccine.2008.09.084","article-title":"Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.","volume":"26","author":"Greenough","year":"2008","journal-title":"Vaccine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0264-410x(03)00538-3","article-title":"Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.","volume":"22","author":"Cosma","year":"2003","journal-title":"Vaccine."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213911","article-title":"Induction and maintenance of bi-functional (IFN-\u03b3 + IL-2+ and IL-2+ TNF-\u03b1+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a phase I trial in India.","volume":"14","author":"Ponnan","year":"2019","journal-title":"PLoS One."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime- boost DNA-MVA-rgp140 \/ GLA vaccines in a phase II randomized factorial trial design.","volume":"12","author":"Viegas","year":"2018","journal-title":"PLoS One."},{"key":"B21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/infdis\/jiy212","article-title":"First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector.","volume":"218","author":"Baden","year":"2018","journal-title":"J Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1016\/j.vaccine.2013.03.017","article-title":"Modified vaccinia virus Ankara: innate immune activation and induction of cellular signalling.","volume":"31","author":"Philip","year":"2013","journal-title":"Vaccine."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011400","article-title":"Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.","volume":"5","author":"N\u00f6rder","year":"2010","journal-title":"PLoS One."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-015-0252-1","article-title":"Modified vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte \/ macrophage lineage.","volume":"12","author":"Lehmann","year":"2015","journal-title":"Virol J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1128\/JVI.00468-14","article-title":"Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.","volume":"88","author":"Royo","year":"2014","journal-title":"J Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1128\/JVI.01884-08","article-title":"Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.","volume":"83","author":"Lehmann","year":"2009","journal-title":"J Virol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1099\/vir.0.79998-0","article-title":"Modified vaccinia virus Ankara induces moderate activation of human dendritic cells.","volume":"85","author":"Drillien","year":"2004","journal-title":"J Gen Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.virol.2006.02.039","article-title":"Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity.","volume":"350","author":"Kastenmuller","year":"2006","journal-title":"Virology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1128\/jvi.02329-09","article-title":"Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.","volume":"84","author":"Brandler","year":"2010","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular mechanism of HIV-1 Entry.","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-1-61779-876-4_4","article-title":"Easy and efficient protocols for working with recombinant vaccinia virus MVA.","volume":"890","author":"Kremer","year":"2012","journal-title":"Methods Mol Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cyto.2018.08.018","article-title":"A high-resolution mass cytometry analysis reveals a delay of cytokines production after TLR4 or TLR7\/8 engagements in HIV-1 infected humans.","volume":"111","author":"Leite Pereira","year":"2018","journal-title":"Cytokine."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0175-8","article-title":"Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.","volume":"5","author":"Palgen","year":"2020","journal-title":"NPJ Vaccines."},{"key":"B34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/cyto.a.23107","article-title":"In depth comparative phenotyping of blood innate myeloid leukocytes from healthy humans and macaques using mass cytometry.","volume":"91","author":"Elhmouzi-younes","year":"2017","journal-title":"Cytom A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nbt.1991","article-title":"Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE.","volume":"29","author":"Qiu","year":"2011","journal-title":"Nat Biotechnol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cyto.a.22271","article-title":"Normalization of mass cytometry data with bead standards.","volume":"83","author":"Finck","year":"2013","journal-title":"Cytom Part A."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.4049\/jimmunol.167.3.1654","article-title":"Lymphocytes from HIV-1-infected individuals.","volume":"167","author":"Rosati","year":"2001","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1023\/a:1013121625962","article-title":"Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: implications for pathogenesis.","volume":"21","author":"Shalekoff","year":"2001","journal-title":"J Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition.","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: cell binding and entry.","volume":"2","author":"Wilen","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism.","volume":"3","author":"McFadden","year":"2005","journal-title":"Nat Rev Microbiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation.","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature."},{"key":"B43","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation.","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/v2020574","article-title":"CCR5: from natural resistance to a new anti-HIV strategy.","volume":"2","author":"Lopalco","year":"2010","journal-title":"Viruses."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1128\/JVI.00444-07","article-title":"Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.","volume":"81","author":"Guerra","year":"2007","journal-title":"J Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-08719-y","article-title":"Modified vaccinia virus ankara preferentially targets antigen presenting cells in vitro, ex vivo and in vivo.","volume":"7","author":"Altenburg","year":"2017","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:implications for use as a human vaccine.","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.","volume":"79","author":"Drexler","year":"1998","journal-title":"J Gen Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-1-4899-1382-1_2","article-title":"Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.","volume":"397","author":"Moss","year":"1996","journal-title":"Adv Exp Med Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1006\/viro.1995.1332","article-title":"Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.","volume":"210","author":"Wyatt","year":"1995","journal-title":"Virology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis.","volume":"410","author":"M\u00fcller","year":"2001","journal-title":"Nature."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.113.007724","article-title":"Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.","volume":"66","author":"Bachelerie","year":"2014","journal-title":"Pharmacol Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.immuni.2012.07.015","article-title":"Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells.","volume":"37","author":"Duffy","year":"2012","journal-title":"Immunity."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01777","article-title":"Characterization of leukocytes from HIV-ART patients using combined cytometric profiles of 72 cell markers.","volume":"10","author":"Leite Pereira","year":"2019","journal-title":"Front Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000499841","article-title":"Mass cytometry reveals the immaturity of circulating neutrophils during SIV infection.","volume":"12","author":"Lemaitre","year":"2019","journal-title":"J Innate Immun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3851\/IMP2357","article-title":"Differential effects of tenofovir\/emtricitabine and abacavir\/lamivudine on human leukocyte recruitment.","volume":"17","author":"De Pablo","year":"2012","journal-title":"Antivir Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3851\/IMP3160","article-title":"Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.","volume":"22","author":"Afonso","year":"2017","journal-title":"Antivir Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood.v82.2.625.bloodjournal822625","article-title":"Antisense oligonucleotides to the p65 subunit of NF-kB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes.","volume":"82","author":"Sokoloski","year":"1993","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.4161\/cc.2.5.465","article-title":"An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.","volume":"2","author":"Dai","year":"2003","journal-title":"Cell Cycle."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1128\/JVI.02267-10","article-title":"Interplay between modified vaccinia virus ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.","volume":"85","author":"Pascutti","year":"2011","journal-title":"J Virol."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-9-15","article-title":"Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.","volume":"9","author":"Liu","year":"2008","journal-title":"BMC Immunol."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cells7080103","article-title":"Understanding the biology of self-renewing macrophages.","volume":"7","author":"R\u00f6szer","year":"2018","journal-title":"Cells."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/478408","article-title":"Innate immune memory: the latest frontier of adjuvanticity.","volume":"2015","author":"T\u00f6pfer","year":"2015","journal-title":"J Immunol Res."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02936","article-title":"Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations.","volume":"9","author":"S\u00e1nchez-Ram\u00f3n","year":"2018","journal-title":"Front Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02096\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T05:59:49Z","timestamp":1599544789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02096\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2020.02096"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02096","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"article-number":"2096"}}